US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Paragon GmbH & Co KGaA (0NFG) 銘柄情報

Paragon GmbH & Co KGaA (0NFG)

35.725

0.00

(0.00%)

終了 6月16日 12:30AM

Paragon GmbH & Co KGaA (0NFG) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

35.725

( - )

買値

34.85

売値

36.60

出来高

0.00

0.00 日の範囲 0.00

35.725 52 週間の範囲 35.725

時価総額

前日終値

35.725

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

849 €

発行済株式数

4,526,266

配当利回り

PER

-1.36

1 株当たり利益 (EPS)

-1.21

歳入

120.77M

純利益

-5.48M

paragon GmbH & Co. KGaA develops, produces, and distributes automotive electronics, body kinematics, and e-mobility solutions for the automotive industry in Germany, European Union, and internationally. It operates through two segments, Electronics and Mechanics. The Electronics segment develops and... paragon GmbH & Co. KGaA develops, produces, and distributes automotive electronics, body kinematics, and e-mobility solutions for the automotive industry in Germany, European Union, and internationally. It operates through two segments, Electronics and Mechanics. The Electronics segment develops and sells sensors, loudspeakers, microphones, batteries, and display instruments primarily for the automotive industry. The Mechanics segment develops and markets electromechanical components for the automotive and mechanical manufacturing industries. paragon GmbH & Co. KGaA was founded in 1988 and is headquartered in Delbrück, Germany. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.paragon.ag

本社

Delbrück, Germany

設立

1988

Paragon GmbH & Co KGaA is listed in the sector of the ロンドン証券取引所 with ticker 0NFG. The last closing price for Paragon GmbH & Co KGaA was 35.73 €. Over the last year, Paragon GmbH & Co KGaA shares have traded in a share price range of 35.725 € to 35.725 €.

Paragon GmbH & Co KGaA currently has 4,526,266 shares in issue. The market capitalisation of Paragon GmbH & Co KGaA is 161.70 € million. Paragon GmbH & Co KGaA has a price to earnings ratio (PE ratio) of -1.36.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	35.725	35.725	35.725	72	35.725	DE
52	0	0	35.725	35.725	35.725	53	35.725	DE
156	0	0	35.725	35.725	35.725	37	35.725	DE
260	0	0	35.725	35.725	35.725	31	35.725	DE

0NFG - Frequently Asked Questions (FAQ)

What is the current Paragon GmbH & Co KGaA share price?

The current share price of Paragon GmbH & Co KGaA is 35.725 €

How many Paragon GmbH & Co KGaA shares are in issue?

Paragon GmbH & Co KGaA has 4,526,266 shares in issue

What is the market cap of Paragon GmbH & Co KGaA?

The market capitalisation of Paragon GmbH & Co KGaA is EUR 161.7M

What is the 1 year trading range for Paragon GmbH & Co KGaA share price?

Paragon GmbH & Co KGaA has traded in the range of 35.725 € to 35.725 € during the past year

What is the PE ratio of Paragon GmbH & Co KGaA?

The price to earnings ratio of Paragon GmbH & Co KGaA is -1.36

What is the cash to sales ratio of Paragon GmbH & Co KGaA?

The cash to sales ratio of Paragon GmbH & Co KGaA is 0.06

What is the registered address of Paragon GmbH & Co KGaA?

The registered address for Paragon GmbH & Co KGaA is Boesendamm 11, Delbrück, North Rhine-Westphalia, 33129

What is the Paragon GmbH & Co KGaA website address?

The website address for Paragon GmbH & Co KGaA is www.paragon.ag

biotechinvestor1

biotechinvestor1 7分前

Total nonsense! I have no interest in educating you.

Nemesis18

Nemesis18 8分前

She'll probably move to somewhere without any extradition treaty once the plug is finally pulled on this 'cancer vaccine' scam.?

price_and_volume

price_and_volume 10分前

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

StockItOut

StockItOut 11分前

WKSP Weekly chart: https://schrts.co/IIIuZpgy

CelestialSage6

CelestialSage6 12分前

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

Wolf-man jack

Wolf-man jack 13分前

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

CV Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a pro

price_and_volume

price_and_volume 15分前

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

mrwrn2010

mrwrn2010 18分前

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

PEACHMAN

PEACHMAN 20分前

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761

IFUS STRONG

price_and_volume

price_and_volume 21分前

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

Homework.Investwell

Homework.Investwell 27分前

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Mdk1

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell 36分前

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal 38分前

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News 44分前

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 48分前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 48分前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 56分前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

biotechinvestor1

biotechinvestor1 59分前

I love it when Alteogen fanboys post on this board. Nearly every time they show up, Halozyme has a run up.

DR_rugby

DR_rugby 59分前

Prophecy is coming

https://www.cnbc.com/2026/06/16/boj-rate-hike-historic-inflation.html

Japanese rates are going higher

Yen is yet to be stabilize

The great unwinding is coming soon

GLTA

Paragon GmbH & Co KGaA

Burgundy Diamond Mines (PK)

Canadian Short Term Bond...

Electra Battery Materials

Eqty Lkd Nts 13/08/26

1.53% 02jul2038 1.53% 02...

Vivione Biosciences

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。